LOTTE Biologics, a contract development and manufacturing organization (CDMO), plans to open a bio plant in Incheon Songdo. Last October, the company signed a land purchase agreement with the Incheon Free Economic Zone Authority to build a plant in Songdo International City, Incheon. By 2030, the company plans to construct three bio plants where it expects to produce a total antibody medicine production capacity of 360,000 liters.

Construction on the plant, which is set to commence this year, will be a mammalian cell culture facility with a production capacity of 120,000 liters. As part of the ‘Titer Flex Quad Bioreactor System, the facility will feature 15,000-liter stainless steel bioreactors for current titer needs as well as 3,000-liter stainless steel bioreactors for high-titer pharmaceutical manufacturing, fulfilling potential client needs for pharmaceutical production while also improving cost-efficiency.

CEO Richard Lee said, “LOTTE Biologics bio plant in Songdo will not just be a production facility but embody innovative solutions for a better human life. We are committed to evolving as a global CDMO, ensuring on-time-in-full delivery of necessary pharmaceuticals to patients.”